Related Experiment Videos
[Cordipine in the treatment of patients with exacerbated coronary disease]
Insights
Adding nifedipine (Cordipin) to standard treatment improved outcomes for 73% of patients with coronary artery disease exacerbations, including those with angina of effort and unstable angina. This pharmacological approach demonstrated good tolerability and safety.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease exacerbations present significant clinical challenges.
- Angina of effort and unstable angina are distinct manifestations requiring effective management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of adding nifedipine (Cordipin) to combined pharmacological treatment in patients with coronary disease exacerbation.
Main Methods:
- A group of 60 patients with coronary disease exacerbation were studied.
- Patients were divided into two subgroups: angina of effort (n=26) and unstable angina (n=34).
- Treatment involved nitrates, beta-blockers, and nifedipine (Cordipin).
Main Results:
- Clinical and electrocardiographic improvement was observed in 44 patients (73%).
- All patients in the subgroup with angina of effort showed improvement.
- 53% of patients in the unstable angina subgroup experienced improvement.
Conclusions:
- Combined pharmacological therapy including nifedipine (Cordipin) is effective for coronary disease exacerbation.
- Nifedipine (Cordipin) demonstrated good tolerability with no serious side effects in this patient group.
Abstract:
The results of pharmacological treatment are presented in a group of 60 patients with exacerbation of coronary disease. The patients were divided into two subgroups: subgroup 1 of 26 patients with intensification of angina of effort, subgroup II of 34 patients with unstable angina. Combined pharmacological treatment was given: nitrates, B-adrenolytic drugs and nifedipine (Cordipin, Krka) Addition of Cordipin produced clinical and electrocardiographic improvement in 44 cases (73%): all patients in subgroup I and 18 (53%) in subgroup II. Cordipin was well tolerated, and produced no serious side effects.